Resmetirom
Cross-source consensus on Resmetirom from 1 sources and 3 claims.
1 sources · 3 claims
Benefits
Risks & contraindications
Background
Highlighted claims
- Resmetirom is a thyroid hormone receptor-beta selective agonist that received FDA approval for MASH in March 2024. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
- Resmetirom's phase 3 trial showed histological benefits including steatohepatitis resolution and fibrosis improvement in the T2DM subgroup. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
- Resmetirom's long-term safety is unknown, with effects on the pituitary-thyroid axis unclear and only 52-week histological data available. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol